Graham Capital Management’s AbbVie ABBV Stock Holding History

Graham Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.21M	Buy	12,752 +253	+2%	+$54.4K	0.06%	240
2026 Q1	$2.72M	Buy	12,499 +5,347	+75%	+$1.19M	0.07%	216
2025 Q4	$1.63M	Buy	7,152 +284	+4%	+$64.7K	0.04%	274
2025 Q3	$1.59M	Sell	6,868 -21,991	-76%	-$4.48M	0.03%	269
2025 Q2	$5.36M	Buy	28,859 +22,125	+329%	+$4.11M	0.08%	135
2025 Q1	$1.41M	Buy	+6,734	New	+$1.31M	0.02%	449
2024 Q1	–	Sell	-4,940	Closed	-$766K	–	1029
2023 Q4	$766K	Buy	+4,940	New	+$720K	0.02%	457
2023 Q3	–	Sell	-2,229	Closed	-$300K	–	981
2023 Q2	$300K	Buy	+2,229	New	+$327K	0.01%	683
2017 Q2	–	Sell	-61,800	Closed	-$4.03M	–	88
2017 Q1	$4.03M	Buy	+61,800	New	+$3.89M	0.16%	54
2015 Q4	–	Sell	-16,000	Closed	-$871K	–	51
2015 Q3	$871K	Buy	+16,000	New	+$1.04M	0.1%	93

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Graham Capital Management's ABBV Position: Q2 2026 in Review

Graham Capital Management increased its AbbVie (ABBV) stake by 2% in Q2 2026, buying an estimated $54.4K and bringing the position to 12,752 shares worth $3.21M. The position accounts for 0.06% of the portfolio, ranked #240.

Graham Capital Management first reported a position in ABBV in Q3 2015 and has held it in 10 quarters since. The position peaked at $5.36M in Q2 2025. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Graham Capital Management held 12,752 shares of AbbVie worth $3.21M as of Q2 2026.
Graham Capital Management bought 253 AbbVie shares in Q2 2026, an estimated $54.4K.
AbbVie made up 0.06% of Graham Capital Management's portfolio in Q2 2026, its #240 holding.
Graham Capital Management first reported a position in AbbVie in Q3 2015 and has held it in 10 quarters since.
Graham Capital Management's AbbVie position peaked at $5.36M in Q2 2025.
4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.